The Latest Analyst Ratings for Legend Biotech
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 15 analysts have published their opinion on Legend Biotech (NASDAQ:LEGN) stock, with 10 bullish and 5 somewhat bullish ratings. The average price target is $77.93, implying an upside from the current price of $69.08. The average price target has increased by 6.39% over the past month.
June 13, 2023 | 5:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech (NASDAQ:LEGN) has received 15 analyst ratings in the past 3 months, with 10 bullish and 5 somewhat bullish ratings. The average price target is $77.93, indicating potential upside.
The 15 analysts covering Legend Biotech have a positive outlook on the stock, with an average price target of $77.93, which is higher than the current price of $69.08. This indicates a potential upside for the stock in the short term. The average price target has also increased by 6.39% over the past month, showing growing optimism among analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100